What are the most common mistakes with Follistatin 344?
The most common Follistatin 344 mistakes are running it longer than 30 days without safety data; treating it as steroid-equivalent (it isn't); stacking with too many other compounds and crediting Follistatin for everything. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for Follistatin 344 is limited.
Common Follistatin 344 mistakes
- Running it longer than 30 days without safety data
- Treating it as steroid-equivalent (it isn't)
- Stacking with too many other compounds and crediting Follistatin for everything
References
- Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors — Haidet AM, Rizo L, Handy C, et al. (incl. Mendell JR, Kaspar BK), PNAS, 2008
- Follistatin gene delivery enhances muscle growth and strength in nonhuman primates — Kota J, Handy C, Haidet AM, et al. (incl. Kaspar BK), Science Translational Medicine, 2009
- A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy — Mendell JR, et al., Molecular Therapy, 2015 (NCT01519349)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Follistatin 344
Last updated 2026-06-15.